Regulus Therapeutics is a San Diego-based biopharmaceutical company focused on developing microRNA-targeted drugs for orphan kidney diseases, including its candidate RGLS8429 for autosomal dominant polycystic kidney disease. The company went public on October 4, 2012, and has 28 employees.
Joseph P Hagan sold 115,290 shares of RGLS on 13 January at $1.26 per share, worth a total of $146K. They now own 222,572 RGLS shares, or a 34% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
